Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease

IF 3.2 4区医学 Q3 CELL BIOLOGY

Immunology & Cell Biology Pub Date : 2024-05-01 DOI:10.1111/imcb.12766

Adrian YS Lee, Joanne H Reed

引用次数: 0

Abstract

CAR T cell therapy is showing remarkable results in autoimmune disease with treatment-refractory patients showing durable drug-free remission. Here, we highlight five key papers from 2023 that are driving the development of CAR T cells to improve precision, safety, efficacy and accessibility for the treatment of autoantibody-associated autoimmune diseases.

Abstract Image

查看原文本刊更多论文

2023 年亮点：CAR T 细胞推动自身免疫性疾病的精准治疗

CAR T细胞疗法在自身免疫性疾病方面取得了令人瞩目的成果，难治性患者出现了持久的无药缓解。在此，我们将重点介绍2023年的五篇重要论文，它们推动了CAR T细胞的发展，提高了治疗自身抗体相关自身免疫性疾病的精确性、安全性、有效性和可及性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology & Cell Biology 医学-免疫学

CiteScore

7.50

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.